FR2838645A1 - Reducing intracellular accumulation of lipids and treating obesity, by oral or local administration of synergistic combination of at least two vitamins and at least two minerals or trace elements - Google Patents
Reducing intracellular accumulation of lipids and treating obesity, by oral or local administration of synergistic combination of at least two vitamins and at least two minerals or trace elements Download PDFInfo
- Publication number
- FR2838645A1 FR2838645A1 FR0204905A FR0204905A FR2838645A1 FR 2838645 A1 FR2838645 A1 FR 2838645A1 FR 0204905 A FR0204905 A FR 0204905A FR 0204905 A FR0204905 A FR 0204905A FR 2838645 A1 FR2838645 A1 FR 2838645A1
- Authority
- FR
- France
- Prior art keywords
- vitamin
- vitamins
- minerals
- trace elements
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Birds (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Pediatric Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
La presente invention concerne l'utilisation d'une composition synergiqueThe present invention relates to the use of a synergistic composition
a base de vitamines, de mineraux et d'oligo-elements pour stimuler l' elimination des lipides intracellulaires. Les vitamines, les mineraux et les oligo-elements vent des micronutriments indispensables au bon fonctionnement metabolique de l'organisme. Les vitamines vent des substances organiques aux structures chimiques variables et parfois complexes, tandis que les mineraux et les oligo-elements ont based on vitamins, minerals and trace elements to stimulate the elimination of intracellular lipids. Vitamins, minerals and trace elements provide micronutrients essential for the metabolic function of the body. Vitamins produce organic substances with variable and sometimes complex chemical structures, while minerals and trace elements have
une origine minerale.a mineral origin.
Ces micronutriments ont chacun un role specifique principal (constitutif, catalytique, coenzyme, prohormone) et aucun d'entre eux ne peut etre remplace par un autre pour These micronutrients each have a specific major role (constitutive, catalytic, coenzyme, prohormone) and none of them can be replaced by another for
assurer le maintien de l'homeostasie. maintain homeostasis.
Les doses actives vent variables. Les vitamines par exemple vent actives a faible dose, les proportions necessaires pour chacune d'elles variant de 1 a 25 000 si l'on prend les extremes que vent respectivement la vitamine The active doses are variable. Vitamins, for example active wind at low dose, the necessary proportions for each of them ranging from 1 to 25,000 if we take the extremes that wind respectively vitamin
B12 pour la plus faible et la vitamine C pour la plus forte. B12 for the weakest and vitamin C for the strongest.
I1 en est de meme pour les oligo-elements. It is the same for trace elements.
Des valeurs choisies par differents experts tenant compte des donnees scientifiques concernant les besoins nutritionnels, les motivations et habitudes alimentaires des groupes concernes (enfants, adolescents, adultes, personnel agees, sportifs...etc.) ont about) a l'etablissement d'Apports Nutritionnels Conseilles (DUPIN H. ABRAHAM J. GIACHETTI I. Apports Nutritionnels conseilles pour la population francaise, Tec & Doc Lavoisier, Paris, 1999) ou d'etablir des Values selected by different experts taking into account the scientific data concerning the nutritional needs, motivations and eating habits of the groups concerned (children, adolescents, adults, senior staff, sportsmen, etc.) were related to the establishment of Nutritional contributions Recommended (DUPIN H. ABRAHAM J. GIACHETTI I. Nutritional contributions advised for the French population, Tec & Doc Lavoisier, Paris, 1999) or to establish
Apports Journaliers Recommandes (AJR). Recommended Daily Contributions (RDA).
Malgre l' existence de ces recommendations, un nombre grandissant d'etudes epidemiologiques realisees dans les pays developpes tendent a demontrer l' existence de carences plus ou moins marquees en fonction des micronutriments et du Despite the existence of these recommendations, a growing number of epidemiological studies carried out in developed countries tend to show the existence of more or less marked deficiencies depending on micronutrients and
segment de population considere.population segment considered.
Selon les resultats de trots enquetes principales menees sur le status nutritionnel des francais, le pourcentage de la population qui ne recoit pas les apports conseilles pour differentes categories de micronutriments est le suivant (SOUCCAR T. CURTAY J.P. Le nouveau guide des vitamines, Editions du Seuil, Paris, 1996, page 11): Vitamines, Pourcentage des Pourcentage des Moyenne mineraux et hommes ne femmes ne oligo-elements recevant pas recevant pas les AJR les AJR Vitamine A 11,7 a 60 8 a 5032, 43 Vitamine B1 43 a 80 69 a 8068,00 Vitamine B2 27 a 60 24,6 a 6042,90 Vitamine B3 49,5 49,349,40 Vitamine B6 67,5 a 80 90 a 9282,38 Vitamine B9 40 a 90 50 a 9067,50 Vitamine C 25 a 60 15 a 6040,00 Vitamine D 90 a 98 90 a 98,694,15 Vitamine E 40 a 100 75 a 10078,75 Magnesium 60 8070,00 Calcium 20 30,025,00 Fer 5 55 a 9038,75 Zinc 80 9085,00 Total 59,56 Ces etudes tendent a demontrer que globalement, 6 a 7 personnel sur 10 environ presentent une deficience plus ou moins complete vis a vis d'au moins une vitamine, un mineral ou un oligo-element mais les consequences exactes de ces differentes deficiences ne vent pas scientifiquement etablies. Par ailleurs, il n'existe aucun aliment qui contient tous ces elements vitaux en quantite suffisante et en According to the results of three main surveys conducted on the nutritional status of the French, the percentage of the population that does not receive the recommended contributions for different categories of micronutrients is as follows (SOUCCAR T. CURTAY JP The new guide of vitamins, Editions du Seuil , Paris, 1996, page 11): Vitamins, Percentage of Percentage of Average Minerals and Men Not Women Not Receiving Oligo-elements Not Receiving RDAs AJR Vitamin A 11.7 to 60 8 to 5032, 43 Vitamin B1 43 to 80 69 to 8068.00 Vitamin B2 27 to 60 24.6 to 6042.90 Vitamin B3 49.5 49,349.40 Vitamin B6 67.5 to 80 90 to 9282.38 Vitamin B9 40 to 90 50 to 9067.50 Vitamin C 25 a 60 15 to 6040.00 Vitamin D 90 to 98 90 to 98,694.15 Vitamin E 40 to 100 75 to 10078.75 Magnesium 60 8070.00 Calcium 20 30.025.00 Iron 5 55 to 9038.75 Zinc 80 9085.00 Total 59,56 These studies tend to show that overall, about 6 to 7 staff out of about 10 have a more or less complete deficiency with respect to less a vitamin, a mineral or a trace element but the exact consequences of these different deficiencies are not scientifically established. On the other hand, there is no food that contains all these vital elements in sufficient quantities and in
proportion adequate.adequate proportion.
Le role exact et complet des vitamines, des mineraux et des oligoelements demeure inconnu. Les proportions respectives entre ces differents elements vitaux ntont par ailleurs jamais ete scientifiquement etablies pour une The exact and complete role of vitamins, minerals and oligoelements remains unknown. The respective proportions between these different vital elements have never been scientifically established for
fonction cellulaire donnee.cellular function.
A ce jour, aucune correlation entre les carences en vitamines, en mineraux et en dToligo-elements et le probleme de surcharge ponderale ou les hypercholesterolemies n'a ete To date, no correlation between vitamin, mineral, and trace element deficiencies and the problem of overweight or hypercholesterolemia has been reported.
scientifiquement etablie.scientifically established.
On observe par ailleurs dans les pays developpes une augmentation considerable de la proportion d'individus (environ 40% de la population) presentant une surcharge In developed countries there is also a considerable increase in the proportion of individuals (about 40% of the population) with an overload.
ponderale marquee et de l'exces de poids. ponderale marke and excess weight.
La surcharge ponderale resulte de ['accumulation de grandes quantites de graisses par certaines cellules de l'organisme, les adipocytes. Ces cellules peuvent stocker de grandes quantites de lipides a l'interieur meme de leur cytoplasme, ce vent les lipides intracellulaires. Ce stockage excessif est en realite lie a la diminution de la capacite Weight overload results from the accumulation of large amounts of fat by certain cells of the body, the adipocytes. These cells can store large quantities of lipids inside their cytoplasm, which is the intracellular lipid. This excessive storage is actually related to the decrease in capacity
d'elimination des dechets et des lipides par les cellules. elimination of waste and lipids by the cells.
De nombreuses strategies ont ete proposees pour diminuer la surcharge ponderale, tel que les regimes alimentaires specifiques (hypocalorique, diete proteinee.), la consommation d'extraits de plantes pour "bruler les graisses", les medicaments pour diminuer la sensation de faim (isomerides) , les traitements hormonaux, la prise en charge medicalisee...etc. Ces traitements provoquent des desequilibres physiologiques qui peuvent aggraver les de ficiences en el ements vi taux, donnent des resul tats temporaires, perturbent la physiologic normale des cellules, provoquent des effete nefastes et toxiques ou induisent un effet rebond plus communement designe sous l' expression de Many strategies have been proposed to reduce overweight, such as specific diets (hypocaloric, protein diet), consumption of plant extracts to "burn fat", drugs to reduce the feeling of hunger (isomerides ), hormonal treatments, medical care ... etc. These treatments result in physiological imbalances which can aggravate functional impairments, give temporary results, disrupt the normal physiology of the cells, cause harmful and toxic effects or induce a more commonly known rebound effect.
"phenomena de Yo-Yo"."Yo-Yo phenomena".
Paradoxalement, alors que le cur du probleme reside dans le dysfonctionnement du metabolisme des adipocytes, aucune de ces strategies d'action plutot generale, ne s'est interessee a la cause meme de la surcharge ponderale qui est Paradoxically, while the heart of the problem lies in the dysfunction of adipocyte metabolism, none of these rather general action strategies have been concerned with the very cause of overweight which is
['accumulation des lipides au niveau intracellulaire. lipid accumulation at the intracellular level.
Il n'existe pas de traitement tenant compte de la diminution de la capacite des cellules a eliminer les depots lipidiques intracellulaires alors que ciest a ce niveau que There is no treatment that takes into account the decrease in the ability of cells to eliminate intracellular lipid deposits, whereas it is at this level that
ce situe la veritable cause de la surcharge ponderale. this is the real cause of overweight.
La presente invention concerne l'utilisation d'une composition synergique par vole vale ou par vole locale a base de vitamines, de mineraux et d'oligo-elements pour stimuler de facon ciblee les capacites d'elimination des cellules afin de diminuer ['accumulation des lipides intracellulaires sans induire de toxicite ni d'effets secondaires. Les produits amincissants pour application locale a base de cafeine ont pour effet de mobiliser les reserves de graisse au niveau sous-cutane mais n'agissent pas sur ['accumulation de graisse dans les tissue profonds. Ils n'ont qu'une action superficielle qui ne permet pas de diminuer la The present invention relates to the use of a synergistic composition by vale vale or local vole based vitamins, minerals and trace elements to target the cell elimination capabilities in order to decrease the accumulation intracellular lipids without inducing toxicity or side effects. Thinning products for local application based on caffeine have the effect of mobilizing the fat reserves at the subcutaneous level but do not act on the accumulation of fat in the deep tissues. They have only a superficial action which does not make it possible to reduce the
surcharge ponderale.overweight.
De nombreuses compositions dietetiques ou pharmaceutiques par vole vale utilisent des produits naturels ou synthetiques, des extraits de plantes connus pour agir sur la surcharge ponderale. Ces compositions associent par exemple l'effet d'extraits de plantes diuretiques, drainantes, qui gonflent dans l'estomac et le tube digestif pour diminuer la sensation de faim mais ces compositions n'ont pas d'effet specifique sur l' elimination des lipides intracellulaires. L'utilisation de principes actifs pharmacologiques (cafeine, ephedrine, alpha et beta agonistes) par vole vale dans les compositions dietetiques Many dietetic or pharmaceutical compositions per vale vale use natural or synthetic products, extracts of plants known to act on overweight. These compositions combine, for example, the effect of diuretic, draining plant extracts that swell in the stomach and the digestive tract to reduce the sensation of hunger, but these compositions have no specific effect on the elimination of lipids. intracellular. The use of pharmacological active principles (caffeine, ephedrine, alpha and beta agonists) per vale vale in dietetic compositions
ou alimentaires est interdite ou reglementairement limitee. or food is prohibited or restricted.
Les medicaments ont un mode daction central (coupe-faim) Medication has a central mode of action (appetite suppressant)
mais ont de nombreux effete secondaires. but have many side effects.
Enfin, il existe sur le marche de tres nombreuses formulations a base de vitamines, de mineraux et oligo elements. Ces produits ont soit une action large et non specifique, soit vent destines a une categoric particuliere de la population (enfants, adolescents, adultes, femmes, seniors) mais il n'existe pas de composition synergique a base de vitamines, de mineraux et d'oligo-elements qui soit destinee a stimuler specifiquement les capacites d'elimination des lipides intracellulaires afin de diminuer Finally, there are many formulations on the market based on vitamins, minerals and trace elements. These products have either a broad and nonspecific action, or wind destined to a particular category of the population (children, adolescents, adults, women, seniors) but there is no synergistic composition based on vitamins, minerals and vitamins. micronutrients that are specifically intended to stimulate the intracellular lipid elimination capabilities to decrease
le poids sans induire de toxicite.the weight without inducing toxicity.
Or la demanderesse a decouvert avec etonnement que l'exces de poids peut etre diminue en un temps tres court sans produire d'effets secondaires par l'utilisation de compositions synergiques associant certaines vitamines, certains mineraux et oligo-elements qui permettent de stimuler Now the applicant has discovered with astonishment that the excess weight can be reduced in a very short time without producing side effects by the use of synergistic compositions combining certain vitamins, certain minerals and trace elements that stimulate
l' elimination des reserves lipidiques intracellulaires. elimination of intracellular lipid pools.
Une composition synergique de vitamines, de mineraux et d'oligo-elements stimulant fortement et specifiquement l 'elimination des lipides intracellulaires n'a jamais ete A synergistic composition of vitamins, minerals and trace elements that strongly stimulate and specifically the elimination of intracellular lipids has never been
decrite.described.
Une augmentation des capacites d'elimination des lipides intracellulaires produit ainsi une diminution du stockage des graisses, de la masse corporelle totale et de la surcharge ponderale. En outre, l'efficacite de ces compositions de vitamines, de mineraux et d'oligo-elements peut etre encore amelioree lorequ'elles vent combinees avec des extraits de plantes connus pour agir sur la surcharge ponderale par vole vale ou par vole locale ou avec un regime alimentaire particulier. L'accumulation des lipides intracellulaires a ete diminuee in vitro par l'utilisation de compositions synergiques associant certaines vitamines, certains mineraux et oligo elements, a des doses comprises entre 15 et 200 pour cent des Apports Journaliers Recommandes (AJR), plus particulierement An increase in intracellular lipid removal capabilities results in decreased fat storage, total body weight, and overweight. In addition, the effectiveness of these vitamin, mineral and trace element compositions can be further improved when combined with plant extracts known to act on pond overload by local or local routes or with a particular diet. The accumulation of intracellular lipids has been decreased in vitro by the use of synergistic compositions associating certain vitamins, certain minerals and trace elements, at doses of between 15 and 200 percent of the Recommended Daily Intakes (RDA), more particularly
50% des A]R.50% of the A] Rs.
Les meilleurs resultats ont ete obtenus avec des associations specifiques comprenant 4 vitamines et 4 mineraux ou oligo-elements: vitamine A, vitamine B2, vitamine B9, vitamine E, magnesium, zinc, cuivre et selenium (diminution de The best results were obtained with specific combinations including 4 vitamins and 4 minerals or trace elements: vitamin A, vitamin B2, vitamin B9, vitamin E, magnesium, zinc, copper and selenium (decrease of
89% des lipides intracellulaires).89% of intracellular lipids).
Les resultats d'une etude clinique de 30 j ours realisee chez des sujets ayant un indice de masse corporelle superieur de 20% par rapport a la normale a permis de montrer que l'utilisation d'une composition synergique contenant au moins deux vitamines parmi la vitamine A, la vitamine B2, la vitamine B9, la vitamine E, avec au moins deux mineraux ou oligo-element parmi le magnesium, le zinc, le cuivre ou le selenium permettait une diminution moyenne du poids corporel de -2,47 kg. Llutilisation de cette composition s'accompagne d'une forte The results of a 30-day clinical study in subjects with a body mass index greater than 20% of normal showed that the use of a synergistic composition containing at least two vitamins in the vitamin A, vitamin B2, vitamin B9, vitamin E, with at least two minerals or trace element among magnesium, zinc, copper or selenium allowed a mean decrease in body weight of -2.47 kg. The use of this composition is accompanied by a strong
amelioration des parametres d'appreciation de l' index de bien- improvement of the parameters of appreciation of the index of
etre. Les resultats sur le poids vent meilleurs que lors de l'utilisation d'un regime hypocalorique seul. L'efficacite de cette composition synergique de vitamines, de mineraux et d'oligo-elements est legerement amelioree lorsqu'elle est utilisee en combinaison avec un complement alimentaire a base de plantes connues pour agir sur la surcharge ponderale ou avec d'autres regimes. Par ailleurs, le poids des volontaires ayant utilise une composition synergique associant des vitamines, des mineraux et des oligo-elements est reste stable a la fin des trots mods de la periode d' observation ce qui n' a pas ete le cas des sujets utilisant un regime hypocalorique senl. Cette observation montre que l'utilisation d'une composition synergique permet en outre de stabiliser le poids be. The results on wind weight are better than when using a low calorie diet alone. The effectiveness of this synergistic composition of vitamins, minerals and trace elements is slightly improved when used in combination with a herbal dietary supplement known to act on overweight or other diets. In addition, the weight of the volunteers who used a synergistic composition associating vitamins, minerals and trace elements remained stable at the end of the trots mods of the period of observation which was not the case of the subjects using a low calorie diet senl. This observation shows that the use of a synergistic composition also makes it possible to stabilize the weight
afin de prevenir l'effet rebond observe a la fin d'un regime. to prevent the rebound effect observed at the end of a diet.
C'est pourquoi la presente demande a pour objet l'utilisation de compositions synergiques contenant des vitamines, des mineraux et des oligo-elements qui permettent de stimuler les capacites d'elimination des lipides intracellulaires pour diminuer la surcharge ponderale en combinaison ou non avec des compositions contenant des plantes connues pour agir sur la surcharge ponderale, avec un regime particulier, un appareil d'exercice physique This is why the subject of the present application is the use of synergistic compositions containing vitamins, minerals and trace elements which make it possible to stimulate the elimination capacities of intracellular lipids in order to reduce ponderal overload, in combination or not with compositions containing plants known to act on overweight, with a particular diet, exercise machine
d'electrostimulation musculaire.of muscle electrostimulation.
Les vitamines, les mineraux et les oligo-elements entrant dans la constitution de ces compositions peuvent provenir de di fferentes origines pour etres as soci es sous differentes formes galeniques dont les modes de preparation The vitamins, minerals and trace elements used in the constitution of these compositions can come from different origins for beings as are under different galenic forms whose modes of preparation
vent familieres a l'homme de ['art.wind familiar to the man of art.
Dans la presente demande et dans ce qui suit, le terme << composition >> selon l' invention vise tent les preparations In the present application and in what follows, the term "composition" according to the invention is intended to mean the preparations
solides que non solides (liquides, semi-liquides, visqueuses). solid rather than solid (liquid, semi-liquid, viscous).
Dans des conditions preferentielles de mise en uvre de l' invention, les compositions vent des preparations pharmaceutiques ou dietetiques pour une utilisation par vole vale. Dans des conditions preferentielles de mise en muvre de l' invention, une telle composition solide peut ainsi se presenter sous forme de poudre lyophilisee ou non, instantaneisee (soupe), sous forme extrudee (granules, filaments, pates), sous forme de sachets, de gelules, de comprimes. Dans des conditions preferentielles de mise en muvre de l' invention, une telle composition non solide peut ainsi se presenter sous forme de solution buyable ou a diluer, de Under preferential conditions of implementation of the invention, the compositions wind pharmaceutical or dietetic preparations for use by vale vale. Under preferential conditions of implementation of the invention, such a solid composition can thus be in the form of lyophilized powder or not, instantaneisee (soup), in extruded form (granules, filaments, pasta), in the form of sachets, gelules, tablets. Under preferential conditions of implementation of the invention, such a non-solid composition can thus be in the form of a solution that can be purchased or diluted,
strop ou d'ampoules monodose.strop or ampoules single dose.
Dans des conditions preferentielles de mise en muvre de ['invention, les compositions vent des preparations pharmaceutiques ou cosmetiques pour une utilisation par vole locale. Selon un mode de realisation avantageux, ces formes galeniques vent des compositions pharmaceutiques a liberation immediate ou prolongee permettant une administration par vole Under preferential conditions of implementation of the invention, the compositions wind pharmaceutical or cosmetic preparations for use by local flies. According to an advantageous embodiment, these galenic forms have pharmaceutical compositions with immediate or prolonged release allowing administration by steal.
locale (creme, gel, systeme transdermique). local (cream, gel, transdermal system).
Selon un mode de realisation avantageux, la composition permettant de stimuler les capacites d'elimination des lipides intracellulaires resulte de l'utilisation d'agents permettant la mise a disposition de l'organisme de vitamines, de mineraux According to an advantageous embodiment, the composition that makes it possible to stimulate the elimination capacities of intracellular lipids results from the use of agents that make available to the body vitamins and minerals.
et d'oligo-elements.and trace elements.
Dans des conditions preferentielles de mise en movre les agents permettant un apport en vitamines pourront etre choisis parmi les formes d'apport usuelles synthetiques ou naturelles de vitamines, une source ou un extrait riche en vitamines. Dans des conditions preferentielles de mise en uvre les agents permettant un apport en mineraux et en oligo elements pourront etre choisis parmi les formes d'apport Under preferential conditions of implementation the agents allowing a vitamin intake may be selected from the usual synthetic or natural intake forms of vitamins, a source or extract rich in vitamins. Under preferential conditions of implementation agents allowing a contribution of minerals and trace elements may be selected from the forms of intake
usuelles synthetiques ou naturelles de mineraux et d'oligo- synthetic or natural uses of minerals and oligo-
elements, une source ou un extrait riche en mineraux ou oligo- elements, a source or extract rich in minerals or oligo-
elements, les levures enrichies en mineraux ou oligo-elements. elements, yeasts enriched with minerals or trace elements.
De tels agents vent par exemple commercialises par la societe QUIMDIS (France) ou par la societe COOPER (Cooperation Such agents wind for example marketed by the company QUIMDIS (France) or by the company COOPER (Cooperation
Pharmaceutique Francaise, France).French Pharmaceutical, France).
La dose usuelle, variable selon la composition choisie peut etre par exemple administree quotidiennement pendant une periode au moins egale a 14 jours, 30 j ours de preference, a des doses comprises entre 15 et 200 pour cent des Apports Journaliers Recommandes (AJR) de chacun de ces The usual dose, which varies according to the composition chosen, may for example be administered daily for a period of at least 14 days, preferably 30 days, at doses of between 15 and 200 percent of the recommended daily intake (RDA) of each. of these
elements, plus particulierement 50% des AJR. elements, especially 50% of RDAs.
Par AJR, on entend la quantite de micronutriment effectivement disponible pour une utilisation par 1lorganisme AJR means the amount of micronutrient actually available for use by the body
et non pas le poids brut de la forme d'apport utilisee. and not the gross weight of the input form used.
Dans des conditions preferentielles de mise en muvre, cette composition est utilisee pour accelerer l' elimination des lipides intracellulaires, la detoxication cellulaire afin de diminuer le poids, agir sur llobesite, le stress, la fatigue, ameliorer la forme physique, le sommeil, les troubles lies a Under preferential conditions of implementation, this composition is used to accelerate the elimination of intracellular lipids, cellular detoxification in order to reduce weight, act on lobesite, stress, fatigue, improve physical fitness, sleep, unrest
l'age ou le desir sexuel.age or sexual desire.
Selon le probleme vise, ces compositions peuvent etre associees avec un medicament, un aliment ou un regime hypocalorique, un produit nutritionnel ou cosmetique pour Depending on the problem, these compositions may be associated with a medicament, a food or a low-calorie diet, a nutritional or cosmetic product for
obtenir des effete synergiques.achieve synergistic effects.
C'est pourquoi la presente invention a encore pour objet la combinaison de compositions synergiques pour stimuler les capacites d'elimination des lipides intracellulaires avec des compositions contenant des plantes ou des agents connus Therefore, the subject of the present invention is also the combination of synergistic compositions for stimulating intracellular lipid removal capabilities with compositions containing known plants or agents.
pour agir sur la surcharge ponderale. to act on overweight.
Dans des conditions preferentielles de mise en muvre de l' invention, on utilise differents principes actifs, Under preferential conditions of implementation of the invention, different active ingredients are used,
notamment des extraits de plante.especially plant extracts.
Par "extrait de plante", l'on entend tent des plantes que des parties de plantes, par exemple et de preference de plante entiere et de preference sechees ou deshydratees, et broyees, ou encore des extraits de telles plantes ou parties de plantes obtenus a l' aide d'au moins un solvent aqueux etfou organique et se presentant sous une forme classiquement By "plant extract" is meant plants which parts of plants, for example and preferably whole plant and preferably dried or dehydrated, and crushed, or extracts of such plants or parts of plants obtained with at least one aqueous and / or organic solvent and in a conventionally
employee en pharmacie ou dietetique, liquide ou solide. employee in pharmacy or dietetic, liquid or solid.
Dans des conditions preferentielles de mise en uvre les extraits de plantes et les agents connus pour agir sur la surcharge ponderal etre choisis parmi le groupe des extraits de plante contenant naturellement des principes actifs stimulant la thermogenese, ou contenant des substances cholagogues et choleretiques, des agents capables de retenir les graisses au Under preferential conditions of implementation, plant extracts and agents known to act on overweight are chosen from the group of plant extracts naturally containing thermogenesis-stimulating active ingredients, or containing cholagogue and choleretic substances, agents able to retain fat at
niveau intestinal ou de stimuler le transit intestinal. intestinal level or stimulate intestinal transit.
Ainsi, on peut trouver dans les compositions selon l' invention, une ou plusieurs substances capables de stimuler la thermogenese, et notamment, de la cafeine ou un extrait de plante riche en cafeine obtenu par exemple a partir des graines de Guarana (Paullinia cupana), un extrait de The vert (Thea sinensis), un extrait de noix de Cola (Cola nitida), des substances choleretiques et cholagogues, de preference la cynarine ou un extrait d'Artichaut (Cynara scolymus), certaines plantes epices, de preference le Gingembre (Zingiber officinalis), des enzymes, de preference la bromelaine ou un extrait d'Ananas (Ananas comosus) riche en bromelaine, la papaine ou un extrait de Papaye (Carica papaya) riche en papaine, des fibres vegetales, notamment les fibres de fruits (citron, pamplemousse, pomme), de cereales, les pectines, les fructo- oligosaccharides, de preference l'inuline, le chitosan, l'argile, de preference une argile verse de type illite a structure phylliteuse, une argile montmorrillonite, Thus, one can find in the compositions according to the invention, one or more substances capable of stimulating thermogenesis, and in particular, caffeine or a plant extract rich in caffeine obtained for example from seeds of Guarana (Paullinia cupana). , an extract of The Green (Thea sinensis), an extract of Cola nut (Cola nitida), choleretic substances and cholagogues, preferably cynarin or an extract of Artichoke (Cynara scolymus), certain herbs, preferably the Ginger (Zingiber officinalis), enzymes, preferably bromelaine or an extract of Pineapple (Ananas comosus) rich in bromelaine, papain or papaya extract (Carica papaya) rich in papain, plant fibers, especially fruits (lemon, grapefruit, apple), cereals, pectins, fructo-oligosaccharides, preferably inulin, chitosan, clay, preferably a clay pour illite type with a phyllitous structure, a montmorrillo clay nite,
kaolinite, attapulgite, sepiolite, smectite et bentonite. kaolinite, attapulgite, sepiolite, smectite and bentonite.
De tels principes actifs ou extraits de plante vent par exemple commercialises par la societe BIOSPHERE (France) ou par la societe GREENTECH (France) ou encore ou par la societe Such active ingredients or plant extracts are sold for example by the company BIOSPHERE (France) or the company GREENTECH (France) or by the company
COOPER (Cooperation Pharmaccutique Francaise, France). COOPER (French Pharmaccutique Cooperation, France).
Ces combinaisons peuvent done se presenter sous forme de poudre lyophilisee ou non, sous forme extrudee (granules, filaments, pates), sous forme de sachets, de gelules, de comprimes. Ces combinaisons peuvent egalement se presenter sous forme d'une preparation pharmaceutique ou cosmetique par vole These combinations can therefore be in the form of lyophilized powder or not, in extruded form (granules, filaments, pasta), in the form of sachets, capsules, tablets. These combinations can also be in the form of a pharmaceutical or cosmetic preparation by steal
locale, creme, gel, systeme transdermique. local, cream, gel, transdermal system.
La presente invention a encore pour objet la combinaison de compositions capables de stimuler les capacites d'elimination des lipides intracellulaires avec un regime alimentaire particulier, un appareil d'exercice physique ou The subject of the present invention is also the combination of compositions capable of stimulating the intracellular lipid elimination capacities with a particular diet, an exercise machine or
d'electrostimulation musculaire.of muscle electrostimulation.
Dans des conditions preferentielles de mise en uvre les regimes alimentaires particuliers pourront etre choisi parmi le groupe des regimes hypocaloriques, des regimes In preferential conditions of implementation the particular diets may be chosen from the group of low calorie diets, diets
hyperproteines, des regimes ameliorant le transit intestinal. hyperproteins, diets that improve intestinal transit.
Dans des conditions preferentielles de mise en muvre, les appareils d'exercice physique ou d'electrostimulation pourront etre des appareils ou des dispositifs permettant de faire travailler les muscles afin d' augmenter la depense Under preferential conditions of implementation, exercise machines or electrostimulation devices may be devices or devices to work the muscles to increase the expense
energetique de liorganisme.energy of the organism.
Les exemples qui suivent illustrent la presente demande. Ces exemples de compositions pour stimuler les capacites d' elimination des lipides intracellulaires ont ete developpes sur la base des resultats obtenus au cours des etudes pharmacologiques. Certaines compositions ont ensuite The following examples illustrate this request. These examples of compositions for stimulating intracellular lipid elimination capabilities have been developed on the basis of results obtained in pharmacological studies. Some compositions then
ete soumises a des experimentations cliniques. have been subjected to clinical trials.
EXEMPLE 1:EXAMPLE 1
On a prepare des gelules, des comprimes et des sachets de vitamines, de mineraux et dioligo-elements repondant a la formule: (en milligrammes par gelules, par comprime ou par sachet) Vitamine A (beta carotene) 24.0000 Vitamine B2 (riboflavine) 0.8000 Vitamine B9 (acide folique) 0.1000 Vitamine E (poudre a 50% de vitamine E) 10.0000 Magnesium (oxyde de magnesium) 248.7000 Zinc (oxyde de zinc) 9.3350 Cuivre (oxyde de cuivre) 1.2520 Selenium (selenate de sodium) 0.0822 Excipient pour les gelules qsp 330 mg Excipient pour les comprimes qsp 400 mg Excipient pour les sachets qsp 1400 mg Posologie: 1 gelule ou 1 comprime chaque matin avec un verre d'eau ou bien 1 sachet pouvant etre melange a un yaourt Pellets, tablets and sachets of vitamins, minerals and dioligo-elements were prepared according to the formula: (in milligrams per capsule, tablet or sachet) Vitamin A (beta carotene) 24.0000 Vitamin B2 (riboflavin) 0.8000 Vitamin B9 (folic acid) 0.1000 Vitamin E (powder with 50% vitamin E) 10.0000 Magnesium (magnesium oxide) 248.7000 Zinc (zinc oxide) 9.3350 Copper (copper oxide) 1.2520 Selenium (sodium selenate) 0.0822 Excipient for gels qs 330 mg Excipient for tablets qs 400 mg Excipient for sachets qs 1400 mg Dosage: 1 gel or 1 tablet each morning with a glass of water or 1 sachet that can be mixed with a yogurt
ou a tout autre aliment.or any other food.
EXEMPLE 2:EXAMPLE 2
On a prepare des gelules de vitamines, de mineraux et d'oligo-elements associes a des extraits de plantes et repondant a la formule: milligrammes / gelule Vitamine A (beta carotene)24.0000 Vitamine B2 (riboflavine)0.8000 Vitamine B9 (acide folique)0.1000 Vitamine E (poudre a 50% de vitamine E)10.0000 Magnesium (oxyde de magnesium)248.7000 Zinc (oxyde de zinc)9.3350 Cuivre (oxyde de cuivre)1.2520 Selenium (selenate de sodium)0.0822 Extrait de guarana a 25% de cafeine naturelle25.0000 Extrait d'artichaut a 1% de cynarine10.0000 Excipients qsp 365 mg Vitamin, mineral and trace element capsules associated with plant extracts have been prepared according to the formula: milligrams / gel Vitamin A (beta carotene) 24.0000 Vitamin B2 (riboflavin) 0.8000 Vitamin B9 (folic acid) 0.1000 Vitamin E (powder with 50% vitamin E) 10.0000 Magnesium (magnesium oxide) 248.7000 Zinc (zinc oxide) 9.3350 Copper (copper oxide) 1.2520 Selenium (sodium selenate) 0.0822 Guarana extract with 25% natural caffeine25 .0000 Artichoke extract with 1% cynarin 10.0000 Excipients qs 365 mg
Posologie: 1 gelule chaque matin avec un verre d'eau. Dosage: 1 gel each morning with a glass of water.
EXEMPLE 3:EXAMPLE 3
On a prepare des comprimes de vitamines, de mineraux et d'oligo-elements associes a des extraits de plantes repondant a la formule: milligrammes / comprime Vitamine A (beta carotene)24.0000 Vitamine B2 (riboflavine)0. 8000 Vitamine B9 (acide folique)0.1000 Vitamine E (poudre a 50% de vitamine E)10.0000 Magnesium (oxyde de magnesium)248.7000 Zinc (oxyde de zinc)9.3350 Cuivre (oxyde de cuivre)1.2520 Selenium (selenate de sodium)0. 0822 Extrait de noix de cola a 25% de cafeine20.0000 Extrait d'ananas10. 0000 Fibres de pamplemousse10.0000 Excipients qsp 400 mg Posologie: 2 comprimes chaque matin avec un verre d'eau. Vitamin, mineral and trace element tablets associated with extracts of plants corresponding to the formula: milligrams / tablet Vitamin A (beta carotene) 24.0000 Vitamin B2 (riboflavin) 0 were prepared. 8000 Vitamin B9 (folic acid) 0.1000 Vitamin E (powder with 50% vitamin E) 10.0000 Magnesium (magnesium oxide) 248.7000 Zinc (zinc oxide) 9.3350 Copper (copper oxide) 1.2520 Selenium (sodium selenate) 0. 0822 Kola nut extract with 25% caffeine20.0000 Pineapple extract10. 0000 Grapefruit Fiber10.0000 Excipients qs 400 mg Dosage: 2 tablets each morning with a glass of water.
EXEMPLE 4:EXAMPLE 4
On a prepare des sachets de vitamines, de mineraux et d'oligo-elements associes a des plantes ou des agents connus pour agir sur la surcharge ponderal repondant a la formule: milligrammes / sachet Vitamine A (beta carotene)24.0000 Vitamine B2 (riboflavine)0.8000 Vitamine B9 (acide folique)0.1000 Vitamine E (poudre a 50% de vitamine E)10.0000 Magnesium (oxyde de magnesium)248.7000 Zinc (oxyde de zinc)9.3350 Cuivre (oxyde de cuivre)1.2520 Selenium tselenate de sodium)0.0822 Inuline de chicoree100. 2160 Extrait de guarana a 25% de cafeine naturelle25.0000 Extrait dTartichaut a 1% de cynarine10.0000 Extrait de the vert a 3% de cafeine naturelle10.0000 Argile verse50.0000 Poubre de jus d'ananas10.0000 Tamarin7.0000 Gingembre7.0000 Gomme Karaya6.0000 Excipients qsp 1400 mg Posologie: 1 sachet par our avec un verre d'eau ou Packets of vitamins, minerals and trace elements associated with plants or agents known to act on the overweight weight answer formula: milligrams / sachet Vitamin A (beta carotene) 24.0000 Vitamin B2 (riboflavin) 0.8000 Vitamin B9 (folic acid) 0.1000 Vitamin E (powder with 50% vitamin E) 10.0000 Magnesium (magnesium oxide) 248.7000 Zinc (zinc oxide) 9.3350 Copper (copper oxide) 1.2520 Sodium selenium tselenate 0.0822 Inulin of chicoree100 . 2160 Guarana extract with 25% natural caffeine25.0000 Artichoke extract with 1% cynarin10.0000 Green tea extract with 3% natural caffeine10.0000 Clay poured50.0000 Poube of pineapple juice10.0000 Tamarin7.0000 Ginger7. 0000 Eraser Karaya6.0000 Excipients qs 1400 mg Dosage: 1 sachet per ou with a glass of water or
melange avec un yaourt, le matin de preference. mixed with a yogurt, preferably in the morning.
EXEMPLE 5EXAMPLE 5
On a prepare des gelules de vitamines, de mineraux et d'oligo-elements repondant a la formule: milligrammes / gelule Vitamine A (beta carotene) 8.0000 Vitamine B1 (chlorhydrate de thiamine) 0.2350 Vitamine B2 (riboflavine) 0.2670 Vitamine B3 (nicotinamide) 3.0000 Vitamine B5 (acide pantothenique) 1.0000 Vitamine B6 (chlorhydrate de pyridoxine) 0.3350 Vitamine B8 (biotine) 0.0250 Vitamine B9 (acide folique) 0.0350 Vitamine B12 (cyanocobalamine) 0.000165 Vitamine C (acide ascorbique) 20.0000 Vitamine E (poudre a 508 de vitamine E) 3.3350 Magnesium (oxyde de magnesium) 83.0000 Calcium (carbonate de calcium) 333.2000 Fer (gluconate de fer) 18.6400 Iode (iodure de potassium) 0.0327 Potassium (chlorure de potassium) 24.4900 Zinc (oxyde de zinc) 3.1120 Cuivre (oxyde de cuivre) 0. 4170 Selenium (selenate de sodium) 0.0274 Excipients qsp 540 mg Posologie: 3 gelules par j our avec un verre d'eau, le Vitamin, mineral and micronutrient capsules were prepared according to the formula: milligrams / gel Vitamin A (beta carotene) 8.0000 Vitamin B1 (thiamine hydrochloride) 0.2350 Vitamin B2 (riboflavin) 0.2670 Vitamin B3 (nicotinamide) 3.0000 Vitamin B5 (Pantothenic Acid) 1.0000 Vitamin B6 (Pyridoxine Hydrochloride) 0.3350 Vitamin B8 (Biotin) 0.0250 Vitamin B9 (Folic Acid) 0.0350 Vitamin B12 (Cyanocobalamin) 0.000165 Vitamin C (Ascorbic Acid) 20.0000 Vitamin E (508 Vitamin Powder E) 3.3350 Magnesium (magnesium oxide) 83.0000 Calcium (calcium carbonate) 333.2000 Iron (iron gluconate) 18.6400 Iodine (potassium iodide) 0.0327 Potassium (potassium chloride) 24.4900 Zinc (zinc oxide) 3.1120 Copper (copper oxide) ) 0. 4170 Selenium (sodium selenate) 0.0274 Excipients qs 540 mg Dosage: 3 capsules per day with a glass of water, the
matin de preference.morning preferably.
EXEMPLE 6:EXAMPLE 6
On a prepare des pates contenant une association de vitamines, de mineraux et d'oligo-elements repondant a la formule:Milligrammes pour 100 grammes de pates Vitamine A (beta carotene)24.000 Vitamine B2 (riboflavine)0.8000 Vitamine B9 (acide folique) 0.1000 Vitamine E (poudre a 50% de vitamine E) 10.0000 Magnesium (oxyde de magnesium) 248.7000 Zinc (oxyde de zinc) 9.3350 Cuivre (oxyde de cuivre) 1.2520 Selenium (selenate de sodium) 0.0822 ufs frais 32 000.0000 Semoule de ble dur qsp 100 grammes Posologie: 100 a 200 grammes de pates par j our cuite a Pasta containing a combination of vitamins, minerals and trace elements has been prepared according to the formula: Milligrams per 100 grams of pasta Vitamin A (beta carotene) 24,000 Vitamin B2 (riboflavin) 0.8000 Vitamin B9 (folic acid) 0.1000 Vitamin E (powder with 50% vitamin E) 10.0000 Magnesium (magnesium oxide) 248.7000 Zinc (zinc oxide) 9.3350 Copper (copper oxide) 1.2520 Selenium (sodium selenate) 0.0822 fresh eggs 32 000.0000 Durum wheat meal qs 100 grams Dosage: 100 to 200 grams of pasta per day cooked a
l'eau.the water.
EXEMPLE 7:EXAMPLE 7
Combinaison de la composition synergique de l'exemple 1 avec 10 g dans 15 centilitres d'eau de soupe deshydratee a base de choux, de legumes et de proteines d'origine laitiere a consommer a volonte. Cette preparation destinee a un regime hypocalorique appauvri en glucides et en lipides, enrich) en proteines et en fibres alimentaires apporte environ 32 Combination of the synergistic composition of Example 1 with 10 g in 15 centilitres of dehydrated soup water based on cabbages, vegetables and proteins of dairy origin to consume at will. This preparation for a reduced calorie diet low in carbohydrates and lipids, enriched in protein and dietary fiber brings about 32
kilocalories pour 10 grammes de soupe deshydratee. kilocalories for 10 grams of dehydrated soup.
EXEMPLE 8:EXAMPLE 8
Combinaison de la composition synergique de l'exemple 1 avec 100 grammes de pates enrichies en proteines a consommer Combination of the synergistic composition of Example 1 with 100 grams of fortified protein-enriched pasta
midi et soir et des legumes verts a volonte. lunch and dinner and green vegetables will.
EXEMPLE g:EXAMPLE g
Combinaison de la composition synergique de l'exemple l avec des sachets de l.4 g chacun, a base de plantes connues pour agir sur la surcharge ponderale repondant a la formule: Pourcentage ponderal Inuline de chicoree 82.555 Soga precuit 2.500 Germe de ble 1.675 Extrait d'Artichaut titre a 3% de cynarine 0.950 Extrait Guarana titre a 10% de cafeine 0.570 Extrait de the vert titre a 3% de cafeine 0.570 Avoine precuite 0.250 Fibres de pomme O.lOO Lithothamne O.lOO Levures 0.025 Arome 0 095 Excipients qsp 100% Posologie: l sachet par j our avec un verre d'eau ou Combination of the synergistic composition of Example 1 with sachets of 14 g each, based on plants known to act on the overweight corresponding to the formula: Percentage weight Inulin of chicoree 82,555 Soga precursor 2,500 Germ of wheat 1,675 Extract artichoke with 3% cynarin 0.950 Guarana extract with 10% caffeine 0.570 Green tea extract with 3% caffeine 0.570 Oat precooked 0.250 Apple fiber O.lOO Lithothamne O.lOO Yeasts 0.025 Aroma 0 095 Excipients qs 100% Dosage: 1 sachet per day with a glass of water or
melange avec un yaourt, le matin de preference. mixed with a yogurt, preferably in the morning.
EXEMPLE lO:EXAMPLE 10
Combinaison de la composition synergique de l'exemple l avec un gel amincissant repondant a la formule: Pourcentage ponderal Cafeine 2.0 Extrait de Centella asiatica 2.0 Extrait de Mimosa tenuiflora l.5 Extrait d'Azadirachta indica 0.6 Extrait de Garcinia cambogia 5.5 Excipients qsp 100% Posologie: appliquer une noix de produit matin et soir et Combination of the synergistic composition of Example 1 with a slimming gel corresponding to the formula: Weight percent Caffeine 2.0 Centella asiatica 2.0 extract Mimosa tenuiflora extract 1.5 Azadirachta indica extract 0.6 Garcinia cambogia extract 5.5 Excipients qs 100% Dosage: apply a nut of product morning and evening and
faire penetrer par un leger massage. to penetrate by a light massage.
EXEMPLE 11:EXAMPLE 11
On a prepare un systeme transdermique de 10 cm2 permettant d'apporter chaque j our a liorganisme les quantites de vitamines, des mineraux et d'oligo-elements indiquees et repondant a la formule: milligrammes / j our Vitamine A (beta carotene)24.000 Vitamine B2 (riboflavine)0.8000 Vitamine B9 (acide folique)0.1000 Vitamine E (poudre a 50% de vitamine E) 10.0000 Magnesium (oxyde de magnesium)248.7000 Zinc (oxyde de zinc)9.3350 Cuivre (oxyde de cuivre)1.2520 Selenium (selenate de sodium)0.0822 Excipients et systeme adhesif transdermique qsp 500 mg A 10 cm 2 transdermal system was prepared to provide each day the vitamins, minerals, and trace minerals indicated and corresponding to the formula: milligrams / day Vitamin A (beta carotene) 24,000 Vitamin B2 (riboflavin) 0.8000 Vitamin B9 (folic acid) 0.1000 Vitamin E (powder with 50% vitamin E) 10.0000 Magnesium (magnesium oxide) 248.7000 Zinc (zinc oxide) 9.3350 Copper (copper oxide) 1.2520 Selenium (sodium selenate) ) 0.0822 Excipients and transdermal adhesive system qs 500 mg
EXEMPLE 12:EXAMPLE 12
Combinaison de la composition de l'exemple 11 avec un systeme transdermique de 10 cm2 permettant d'apporter chaque j our a l'organisme les quantites indiquees d'agents connus pour agir sur la surcharge ponderale et des extraits de plantes repondant a la formule: milligrammes / j our Cafeine 10.0 Extrait de Guarana 20.0 Extrait de Fucus 10.0 Excipients et systeme adhesif transdermique qsp 500 mg La presente invention a encore pour objet un procede de preparation des compositions ci-dessus decrites, caracterise en ce que l'on melange, selon des methodes connues en elles-memes, le ou les principes actifs avec des excipients ou solvents acceptables, notamment pharmaceutiquement ou cosmetiquement Combination of the composition of Example 11 with a 10 cm 2 transdermal system making it possible to supply each day to the body the indicated amounts of agents known to act on overweight and plant extracts corresponding to the formula: milligrams / day Caffeine 10.0 Guarana extract 20.0 Extract of Fucus 10.0 Excipients and transdermal adhesive system qs 500 mg The present invention further relates to a process for the preparation of the compositions described above, characterized in that it is mixed, according to methods known per se, the active ingredient (s) with acceptable excipients or solvents, in particular pharmaceutically or cosmetically
acceptables ou acceptables dans l'alimentation. acceptable or acceptable in the diet.
ETUDES DE TOLERANCE:TOLERANCE STUDIES:
Les etudes de toxicite aigue chez le rat realisees selon les lignes directrices de l'OCDE n 401 sous couvert d' assurance qualite montrent que les preparations utilisees par vole vale presentees en exemple vent non toxiques a la Acute rat toxicity studies carried out in accordance with OECD Guidelines No. 401 under quality assurance conditions show that the preparations used in the study are presented as a non-toxic example.
dose de 5 g/kg.dose of 5 g / kg.
Les etudes de tolerance locale cutanee et de tolerance oculaire chez le lapin realisees selon la methode officielle pour l' appreciation de l'agressivite superficielle cutanee (Arrete du 11 mai 1993) et la methode officielle pour l' evaluation de l' irritation oculaire (Arrete du 9 juin 1992) sous couvert d' assurance qualite montrent que les preparations utilisees par vole locale presentees en exemple Local cutaneous tolerance and ocular tolerance studies in rabbits performed according to the official method for the assessment of cutaneous superficial aggression (Order of 11 May 1993) and the official method for the evaluation of ocular irritation (Order of June 9, 1992) under quality assurance show that the preparations used by the local community presented as an example
vent non irritantes.non-irritating wind.
ETUDE PHARMACOLOGIOUE: Recherche d' associations d'agents capables de stimuler les capacites d' elimination cellulaire PHARMACOLOGICAL STUDY: Investigation of agent associations capable of stimulating cell elimination capabilities
pour diminuer ['accumulation des lipides intracellulaires. to decrease the accumulation of intracellular lipids.
Pour evaluer l'effet des vitamines, des mineraux et des oligo-elements sur la capacite des cellules a eliminer les depots de lipides intracellulaires, des cultures in vitro de cellules musculaires lisses ont ete preparees sur des lamelles en plastique de 1 cm de diametre selon la methode decrite par Shrivastava et al. (Mesh. Find. Exp. Clin. Pharmacol., 15, 345-350, 1993.). Une culture monocouche a 50 % de confluence a ete obtenue en 4 jours. Le serum hyperlipidemique de lapin a ete ajoute au milieu de culture, les cellules ont ete incubees a 37 C et 5% de C02 pendant 48 heures et les depots de lipides intracytoplasmiques ont ete quantifie. Le milieu de culture a ensuite ete remplace par un milieu blanc predefini a 1% de serum de veau ftal mais ne To evaluate the effect of vitamins, minerals and trace elements on the ability of cells to remove intracellular lipid deposits, in vitro cultures of smooth muscle cells were prepared on plastic slides 1 cm in diameter according to the method described by Shrivastava et al. (Mesh, Pharmacol., Clinical Exp., 15, 345-350, 1993.). A monolayer culture at 50% confluence was obtained in 4 days. The rabbit hyperlipidemic serum was added to the culture medium, the cells were incubated at 37 ° C and 5% CO2 for 48 hours and the intracytoplasmic lipid deposits were quantified. The culture medium was then replaced by a white medium predefined at 1% fetal calf serum but not
contenant pas de vitamines, de mineraux et d'oligo-elements. containing no vitamins, minerals and trace elements.
Les concentrations desirees de vitamines, de mineraux et d'oligo-elements ont ete preparees dans le milieu blanc predefini en dissolvent les substances testees dans le milieu et en remplacant le milieu de culture original par le milieu The desired concentrations of vitamins, minerals and trace elements were prepared in the pre-defined white medium by dissolving the substances tested in the medium and replacing the original culture medium with the medium.
contenant les produits a tester.containing the products to be tested.
La cytotoxicite de chaque vitamine, mineral ou oligo- The cytotoxicity of each vitamin, mineral or oligo-
element a ete prealablement determinee. Aucune des concentrations utiliseen'etait cytotoxique. La concentration de produit teste representait 1/100 des Apports Journaliers element has been previously determined. None of the concentrations used was cytotoxic. The concentration of product tested represented 1/100 of the daily contributions
Recommandes (AJR) par millilitre de milieu de culture. Recommends (RDA) per milliliter of culture medium.
Les produits testes etaient les suivants: vitamine A (beta carotene), vitamine B1 (chlorhydrate de thiamine), vitamine B2 (ribeflavine), Vitamine B3 ou PP (nicotinamide), vitamine B5 (acide pantothenique), vitamine B6 (chlorhydrate de pyridoxine), Vitamine B8 ou H. vitamine B9 (acide folique), vitamine B12 (cyanocobalamine), vitamine C (acide ascorbique), vitamine E (acetate de tocopherol), fer (gluconate de fer), lode (iodure de potassium), potassium (chlorure de potassium), zinc (oxyde de zinc), cuivre (oxyde de cuivre), magnesium (oxyde de magnesium), calcium (gluconate de calcium), selenium (selenate de sodium). Seuls les elements ayant montre une certaine activite lors de l'etape de selection preliminaire ont ete retenus pour les The tested products were: vitamin A (beta carotene), vitamin B1 (thiamine hydrochloride), vitamin B2 (ribeflavine), vitamin B3 or PP (nicotinamide), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine hydrochloride) , Vitamin B8 or vitamin B9 (folic acid), vitamin B12 (cyanocobalamin), vitamin C (ascorbic acid), vitamin E (tocopherol acetate), iron (iron gluconate), lode (potassium iodide), potassium ( potassium chloride), zinc (zinc oxide), copper (copper oxide), magnesium (magnesium oxide), calcium (calcium gluconate), selenium (sodium selenate). Only items that showed some activity during the preliminary selection stage were selected for
experiences suivantes.following experiences.
Les depots de lipides intracellulaires ont ete evalues 3 j ours apres exposition aux produits testes selon la Intracellular lipid deposits were evaluated 3 days after exposure to the products tested according to the
methode decrite par Shrivastava et al. (Mesh. Find. Exp. method described by Shrivastava et al. (Mesh, Find, Exp.
Clin. Pharmacol., 15, 345-350, l9g3.). Les resultats ont ete exprimes sous forme de pourcentage de diminution moyen des depots de lipides intracellulaires par rapport aux cultures temoin non traitees considerees comme contenant 100% de depot lipidiques. Les resultats suivants ont ete obtenus avec les produits testes seuls (tableau 1), avec les associations de deux produits (tableau 2) et avec les associations Clin. Pharmacol., 15, 345-350, 1988). The results were expressed as a percentage of average decrease in intracellular lipid stores relative to untreated control cultures considered to contain 100% lipid deposition. The following results were obtained with the products tested alone (Table 1), with the associations of two products (Table 2) and with the associations
synergiques de plusieurs micronutriments(tableau 3). synergistic effects of several micronutrients (Table 3).
Tableau 1 Pourcentage de diminution des depots de lipides intracellulaires avec les produits testes seuls (n=24). Element Concentration Pourcentage de Testee en ug/ml diminution (0,016% des AJR) des lipides intracellulaires Vitamine A 8,0 12,6 + 2,3 Vitamine B1 0,23 7,7 + 1,4 Vitamine B2 0,26 14,5 + 3,9 Vitamine B3 3,0 2,5 + 1,0 Vitamine B5 1,0 4,5 + 2,1 Vitamine B6 0,335 9,9 + 2,9 Vitamine B8 0,025 1, 8 + 0,7 Vitamine B9 0,035 17,5 + 4,6 Vitamine B12 0,0001 8,2 + 2,5 Vitamine C 20,0 11,2 + 4,1 Vitamine E 3,33 21,4 + 3,9 Magnesium 66,67 22, 0 + 5,2 Calcium 178,0 0 Fer 18,64 6,3 +2,7 Iode 0,03 0 Potassium 24,49 0 Zinc 3,11 16,3 + 4,4 Cuivre 0,42 24,3 + 6,2 Selenium 0,013 24,4 + 5,3 Ces resultats montrent que les produits testes seuls n'ont pas d'effet sur la diminution de ['accumulation des dechets lipidiques intracellulaires sauf pour la vitamine A, la vitamine B2, la vitamine B9, la vitamine E, le magnesium, Table 1 Percent decrease in intracellular lipid deposits with test products alone (n = 24). Element Concentration Percentage of Testee in μg / ml decrease (0.016% of RDA) of intracellular lipids Vitamin A 8.0 12.6 + 2.3 Vitamin B1 0.23 7.7 + 1.4 Vitamin B2 0.26 14, 5 + 3.9 Vitamin B3 3.0 2.5 + 1.0 Vitamin B5 1.0 4.5 + 2.1 Vitamin B6 0.335 9.9 + 2.9 Vitamin B8 0.025 1, 8 + 0.7 Vitamin B9 0.035 17.5 + 4.6 Vitamin B12 0.0001 8.2 + 2.5 Vitamin C 20.0 11.2 + 4.1 Vitamin E 3.33 21.4 + 3.9 Magnesium 66.67 22 , 0 + 5.2 Calcium 178.0 0 Iron 18.64 6.3 +2.7 Iodine 0.03 0 Potassium 24.49 0 Zinc 3.11 16.3 + 4.4 Copper 0.42 24.3 + 6.2 Selenium 0.013 24.4 + 5.3 These results show that the products tested alone have no effect on the decrease in the accumulation of intracellular lipid waste except for vitamin A, vitamin B2, vitamin B9, vitamin E, magnesium,
le zinc, le cuivre et le selenium.zinc, copper and selenium.
Tableau 2: Pourcentage de diminution des depots de lipides intracellulaires avec les associations de deux produits (n=24) Pourcentage de diminution des lipides intracellulaires Vitamine A + vitamine B2 20,2 + 4,6 Vitamine A + vitamine B9 26,3 + 5,5 Vitamine A + vitamine E 29,2 + 6,7 Vitamine A + magnesium 26,1 + 4,4 Vitamine A + zinc 18,3 + 4,4 Vitamine A + cuivre 21,3 + 9,1 Vitamine A + selenium 17,2 + 6,1 Vitamine B2 + vitamine B9 18,3 _ 2,7 Vitamine B2 + vitamine E 20,0 + 4,1 Vitamine B2 + magnesium 30,2 + 8,1 Vitamine B2 + zinc 21,1 6,6 Vitamine B2 + cuivre 23,3 + 7,3 Vitamine B9 + vitamine E 24,4 + 6,6 Vitamine B9 + magnesium 18,1 + 8,2 Vitamine B9 + zinc 18,4 + 3,2 Vitamine B9 + cuivre 22,6 _ 4,9 Vitamine E + magnesium 25,9 _ 4,9 Vitamine E + zinc 26,6 + 7,6 Vitamine E + cuivre 17,7 _ 2,7 Zinc + cuivre 16,6 + 4,9 Zinc + magnesium 21,9 + 7,2 Cuivre + magnesium 24,6 + 6,2 Vitamine B2 + selenium 24,6 + 2,7 Vitamine E + selenium 22,2 + 7,8 Magnesium + selenium 23,7 + 8,2 Ces resultats montrent que ['association de deux vitamines, mineraux ou oligo-elements n'ameliore pas l' elimination des lipides intracellulaires. L'activite n'est pas additive. L'activite de l' association de magnesium et de vitamine B2 est superieure a celle des deux elements pris separement. Tableau 3: Pourcentage de diminution des depots de lipides intracellulaires avec les associations synergiques de plusieurs micronutriments (n=24) eventuellement en combinaison avec des extraits de plantes. (vitamine A = A, vitamine B2 = B2 et ainsi de suite pour les vitamines; les symboles internationaux de la table periodique des elements Table 2: Percentage decrease in intracellular lipid deposits with combinations of two products (n = 24) Percent decrease in intracellular lipids Vitamin A + vitamin B2 20.2 + 4.6 Vitamin A + vitamin B9 26.3 + 5 , 5 Vitamin A + Vitamin E 29.2 + 6.7 Vitamin A + Magnesium 26.1 + 4.4 Vitamin A + Zinc 18.3 + 4.4 Vitamin A + Copper 21.3 + 9.1 Vitamin A + selenium 17.2 + 6.1 Vitamin B2 + vitamin B9 18.3 _ 2.7 Vitamin B2 + vitamin E 20.0 + 4.1 Vitamin B2 + magnesium 30.2 + 8.1 Vitamin B2 + zinc 21.1 6.6 Vitamin B2 + copper 23.3 + 7.3 Vitamin B9 + vitamin E 24.4 + 6.6 Vitamin B9 + magnesium 18.1 + 8.2 Vitamin B9 + zinc 18.4 + 3.2 Vitamin B9 + copper 22.6 _ 4.9 Vitamin E + magnesium 25.9 _ 4.9 Vitamin E + zinc 26.6 + 7.6 Vitamin E + copper 17.7 _ 2.7 Zinc + copper 16.6 + 4 , 9 Zinc + magnesium 21.9 + 7.2 Copper + magnesium 24.6 + 6.2 Vitamin B2 + selenium 24.6 + 2.7 Vitamin E + selenium 22.2 + 7.8 Magnesium + selenium 23.7 + 8.2 These results They show that the combination of two vitamins, minerals or trace elements does not improve the elimination of intracellular lipids. The activity is not additive. The activity of the combination of magnesium and vitamin B2 is greater than that of the two elements taken separately. Table 3: Percentage decrease in intracellular lipid deposits with synergistic combinations of several micronutrients (n = 24) possibly in combination with plant extracts. (vitamin A = A, vitamin B2 = B2 and so on for vitamins, the international symbols of the periodic table of elements
designe les mineraux et les oligo-element correspondents). designates the corresponding minerals and trace elements).
Pourcentage de diminution des lipides intracellulaires Percentage of decrease in intracellular lipids
A + B2 + B9 + E 26.4 + 6.9A + B2 + B9 + E 26.4 + 6.9
A + B2 + Mg + Zn 70.0 + g.3A + B2 + Mg + Zn 70.0 + g.3
A + B5 + B6 + B8 22.4 7.6A + B5 + B6 + B8 22.4 7.6
A + Fe + I + K 15.3 + 4.3 B9 + Fe+ Mg + Zn 31.2 + 8.4 A + B2+ Cu + Se 68. 4 + 8.8 A + B2 + Mg + Se 81.2 + 11.4 B5 + B6 + Cu + Se cytotoxique B2 + B9 + Mg + Zn 68.8 + 11.4 B2+ B9 + Zn + Se 77.3 + 9.9 B2 + B9 + Mg + Se 76. 3 + 13.2 B2 + B9 + Cu + Se 80.4 + 8.2 B2 + Mg + Cu + Se 34.9 + 6.7 B5 + B6 + B8 + Fe + 24.6 + 7.2 A + B2 + Mg + Cu 76.3 + 14.6 B2 + B9 + E + Zn 42.6 + 14.6 D + E+ Zn + Si 52.0 _ 9.0 E + Ca + Fe + Cr 36.4 + 8.8 A + B2 + B9 + E + Mg + Zn + Cu + Se 89.2 + 12.6 A + B2 + B9 + Mg + Zn + Cu + Se 72.1 + 11.6 B2 + B9 + E + Mg + Zn + Cu +Se 81.6 + 12.0 A + E + Mg + Zn + Cu + Se 71.6 + 9.9 A + E + Zn + Cu + Se 61.4 + 13.0 E + Mg + Zn + Cu + Se 40.1 + 8.8 A + B2 + Mg + Cu + cafeine (0.01%) 84.4 _ 14.6 A + B2 + Mg + Cu + Phytoestrogenes de soja (10%) 83.4 _ 17.3 Les resultats montrent que pour eliminer les lipides intracellulaires, il est indispensable d'associer au moins deux vitamines parmi la vitamine A, la vitamine B2, la vitamine B9 et au moins deux mineraux ou oligo-elements parmi le magnesium, le zinc, le cuivre et le selenium. Les A + Fe + I + K 15.3 + 4.3 B9 + Fe + Mg + Zn 31.2 + 8.4 A + B2 + Cu + Se 68. 4 + 8.8 A + B2 + Mg + Se 81.2 + 11.4 B5 + B6 + Cu + Se cytotoxic B2 + B9 + Mg + Zn 68.8 + 11.4 B2 + B9 + Zn + Se 77.3 + 9.9 B2 + B9 + Mg + Se 76. 3 + 13.2 B2 + B9 + Cu + Se 80.4 + 8.2 B2 + Mg + Cu + Se 34.9 + 6.7 B5 + B6 + B8 + Fe + 24.6 + 7.2 A + B2 + Mg + Cu 76.3 + 14.6 B2 + B9 + E + Zn 42.6 + 14.6 D + E + Zn + If 52.0 _ 9.0 E + Ca + Fe + Cr 36.4 + 8.8 A + B2 + B9 + E + Mg + Zn + Cu + Se 89.2 + 12.6 A + B2 + B9 + Mg + Zn + Cu + Se 72.1 + 11.6 B2 + B9 + E + Mg + Zn + Cu + Se 81.6 + 12.0 A + E + Mg + Zn + Cu + Se 71.6 + 9.9 A + E + Zn + Cu + Se 61.4 + 13.0 E + Mg + Zn + Cu + Se 40.1 + 8.8 A + B2 + Mg + Cu + caffeine (0.01%) 84.4 _ 14.6 A + B2 + Mg + Cu + Soy Phytoestrogens (10%) 83.4 _ 17.3 The results show that in order to eliminate intracellular lipids, it is essential to combine at least two vitamins among vitamin A and vitamin B2. vitamin B9 and at least two minerals or trace elements among magnesium, zinc, copper and selenium. The
meilleurs resultats vent obtenus en associant ces 8 elements. best wind results obtained by combining these 8 elements.
L'activite diminue en l' absence de l'un de ces elements. Activity decreases in the absence of any of these elements.
ETUDE CLINIQUE: Confirmation des resultats chez l'homme Des gelules, des comprimes et des sachets contenant % des AJR en vitamine A, B2, B9, E, en magnesium, zinc, cuivre et selenium, ont ete prepares (l gelule ou l comprime CLINICAL STUDY: Confirmation of results in humans Gelules, tablets and sachets containing% RDA in vitamin A, B2, B9, E, magnesium, zinc, copper and selenium were prepared (gel or tablet).
ou l sachet par j our selon la forme utilisee). or the sachet per day according to the form used).
Des volontaires adultes de sexe masculin (environ %) ou feminin (environ 65%) ayant un indice de masse corporelle de 20% superieur a la normale ont ete selectionnes pour evaluer l'effet de differents regimes sur l' evolution du poids corporel sur une periode de 30 j ours. Le poids des volontaires a egalement ete evalue 3 mods apres la date de Adult male volunteers (approximately%) or female volunteers (approximately 65%) with a body mass index of 20% above normal were selected to evaluate the effect of different diets on body weight period of 30 days. The weight of the volunteers was also evaluated 3 mods after the date of
debut de l' etude.beginning of the study.
La diminution du poids corporel etait liee a ['amelioration des fonctions metaboliques cellulaires qui facilite l' elimination des lipides intracellulaires et des dechets de l'organisme. L'effet sur differents parametres de bien etre a ete evalue en utilisant des echelles de scores allant de O a 4. Cinq groupes etudies dans des conditions identiques ont ete constitues pour l' etude conduite par un Institut de recherche accredite par le Ministere de la The decrease in body weight was related to the enhancement of cellular metabolic functions which facilitates the removal of intracellular lipids and wastes from the body. The effect on different wellbeing parameters was evaluated using scales of scores ranging from 0 to 4. Five groups studied under identical conditions were formed for the study conducted by a research institute accredited by the Ministry of Health.
Recherche.Research.
Groupe l: complement alimentaire de vitamines, de Group 1: dietary supplement of vitamins,
mineraux et d'oligo-elements selon l'exemple l. minerals and trace elements according to Example 1.
Groupe 2: combinaison d'un complement alimentaire de vitamines, de mineraux et d'oligo-elements associe a un Group 2: combination of a dietary supplement of vitamins, minerals and trace elements associated with a
complement alimentaire a base de plantes selon l'exemple 9. Herbal dietary supplement according to Example 9.
oroupe 3: combinaison d'un complement alimentaire de vitamines, de mineraux et d'oligo-elements associe a un regime contenant des legumes verts a volonte, des fruits et grammes de pates hyperproteinees a consommer midi et soir oroupe 3: combination of a dietary supplement of vitamins, minerals and trace elements associated with a diet containing green vegetables at will, fruits and grams of pasta hyperproteines to consume noon and evening
selon l'exemple 8.according to Example 8.
Groupe 4: regime a base de soupe de legumes lyophilisee sous forme de preparation instantanee a melanger avec de l'eau bouillante. Groupe 5: combinaison d'un complement alimentaire de vitamines, de mineraux et d'oligo-elements associe a regime a base de soupe de legumes lyophilisee sous forme de preparation instantanee a melanger avec de l'eau bouillante Group 4: diet based on freeze-dried vegetable soup as an instant preparation to mix with boiling water. Group 5: combination of a dietary supplement of vitamins, minerals and trace elements associated with a diet of freeze-dried vegetable soup in the form of instant preparation to be mixed with boiling water
selon liexemple 7.according to example 7.
Les resultats moyens suivants ont ete obtenus: Nombre de Perte de poids Index de volontaires moyenne en bien-etre jours (1 a 4) HF H FMoyenne Groupe 1: 830 -2.22 -2.61-2.47 3.21 Groupe 2: 918 -3.67 -3. 82-3.76 3.42 Groupe 3: 412 -2.10 -2.93-2.62 3.11 Groupe 4: 714 -1.15 -1. 30-1.22 1.80 Groupe 5: 1218 -2.20 -2.75-2.56 2.89 Ces resultats montrent que 1lassociation de 50% des AJR en vitamine A, vitamine B2, vitamine B9, vitamine E, magnesium, zinc, cuivre et selenium, diminue le poids chez les hommes et chez les femmes (moyenne de -2.47 kg en 30 j ours) en accelerant l' elimination des lipides intracellulaires. Une amelioration des resultats est obtenue lorsque la composition synergique est combinee avec un complement alimentaire a base de plantes. Ces resultats peuvent egalement etres ameliores en combinaison avec d'autres regimes mais la diminution de poids supplementaire obtenue n'est pas tonj ours significative ce qui montre que la plus grande part de la perte de poids observee est due a la composition synergique de vitamines (A, B2, B9, E), de mineraux The following average results were obtained: Number of Weight Loss Average Volunteer Index in Well-Being Days (1 to 4) HF H Female Group 1: 830 -2.22 -2.61-2.47 3.21 Group 2: 918 -3.67 -3. 82-3.76 3.42 Group 3: 412 -2.10 -2.93-2.62 3.11 Group 4: 714 -1.15 -1. 30-1.22 1.80 Group 5: 1218 -2.20 -2.75-2.56 2.89 These results show that the combination of 50% of the RDAs in vitamin A, vitamin B2, vitamin B9, vitamin E, magnesium, zinc, copper and selenium, decreases the weight in men and women (average of -2.47 kg in 30 days) by accelerating the elimination of intracellular lipids. An improvement in the results is obtained when the synergistic composition is combined with a herbal dietary supplement. These results can also be improved in combination with other diets, but the additional weight reduction obtained is not significant, showing that most of the observed weight loss is due to the synergistic composition of vitamins ( A, B2, B9, E), minerals
et d'oligo-elements (magnesium, zinc, cuivre, selenium). and trace elements (magnesium, zinc, copper, selenium).
Les volontaires du groupe 4 recevant seulement un regime a base de soupe de legume ont montre une diminution de poids tres inferieure aux groupes recevant la composition Group 4 volunteers receiving only a diet of vegetable soup showed a decrease in weight much lower than the groups receiving the composition
synergique de vitamines, de mineraux et d'oligo-elements. synergistic of vitamins, minerals and trace elements.
Par ailleurs, le poids des volontaires ayant utilise une composition synergique associant des vitamines, des mineraux et des oligo-elements est reste stable a la fin des trots mods de la periode d' observation ce qui n'a pas ete le cas des sujets utilisant un regime hypocalorique senl. Cette observation montre que l'utilisation d'une composition synergique permet en outre de stabiliser le poids afin de Moreover, the weight of the volunteers who used a synergistic composition associating vitamins, minerals and trace elements remained stable at the end of the trots mods of the period of observation which was not the case of the subjects using a low calorie diet senl. This observation shows that the use of a synergistic composition also makes it possible to stabilize the weight in order to
prevenir l'effet rebond observe a la fin d'un regime. prevent the rebound effect observed at the end of a diet.
Chez les sujets etudies, l' index de bien-etre a ete fortement augmente avec la composition synergique de vitamines, de mineraux et d'oligoelements qui ameliore remarquablement les parametres d' evaluation du stress, du sommeil, de la forme physique et de la fatigue ce qui montre que la composition synergique de vitamine A, vitamine B2, vitamine B9, vitamine E, magnesium, zinc, cuivre et selenium In the subjects studied, the index of well - being was strongly increased with the synergistic composition of vitamins, minerals and oligoelements which remarkably improved the parameters of stress, sleep, physical fitness and fatigue which shows that the synergistic composition of vitamin A, vitamin B2, vitamin B9, vitamin E, magnesium, zinc, copper and selenium
exerce une action favorable sur la sante en general. has a positive effect on health in general.
Claims (9)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0204905A FR2838645B1 (en) | 2002-04-19 | 2002-04-19 | NOVEL SYNERGISTIC COMPOSITIONS OF VITAMINS, MINERALS AND TRACE ELEMENTS TO STIMULATE THE ELIMINATION OF INTRACELLULAR LIPIDS |
AU2003254759A AU2003254759B2 (en) | 2002-04-19 | 2003-10-17 | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
CA2446254A CA2446254C (en) | 2002-04-19 | 2003-10-22 | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
JP2003364492A JP2005126379A (en) | 2002-04-19 | 2003-10-24 | New synergetic composition of vitamins, minerals and trace element for stimulating elimination of intracellular lipid deposit |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0204905A FR2838645B1 (en) | 2002-04-19 | 2002-04-19 | NOVEL SYNERGISTIC COMPOSITIONS OF VITAMINS, MINERALS AND TRACE ELEMENTS TO STIMULATE THE ELIMINATION OF INTRACELLULAR LIPIDS |
AU2003254759A AU2003254759B2 (en) | 2002-04-19 | 2003-10-17 | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
CA2446254A CA2446254C (en) | 2002-04-19 | 2003-10-22 | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
JP2003364492A JP2005126379A (en) | 2002-04-19 | 2003-10-24 | New synergetic composition of vitamins, minerals and trace element for stimulating elimination of intracellular lipid deposit |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2838645A1 true FR2838645A1 (en) | 2003-10-24 |
FR2838645B1 FR2838645B1 (en) | 2004-05-28 |
Family
ID=34714413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0204905A Expired - Fee Related FR2838645B1 (en) | 2002-04-19 | 2002-04-19 | NOVEL SYNERGISTIC COMPOSITIONS OF VITAMINS, MINERALS AND TRACE ELEMENTS TO STIMULATE THE ELIMINATION OF INTRACELLULAR LIPIDS |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2005126379A (en) |
AU (1) | AU2003254759B2 (en) |
CA (1) | CA2446254C (en) |
FR (1) | FR2838645B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1598063A1 (en) * | 2003-10-22 | 2005-11-23 | Ravi Shrivastava | Synergic compositions comprising vitamins, minerals and trace elements to stimulate removal of intracellular lipids |
FR2883472A1 (en) * | 2005-03-23 | 2006-09-29 | Biolog Vegetale Yves Rocher Sa | Use of a chlorogenic acid in active agents for slimming in cosmetics |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927614B2 (en) * | 2006-02-03 | 2011-04-19 | Jr Chem, Llc | Anti-aging treatment using copper and zinc compositions |
US8491937B2 (en) * | 2007-02-15 | 2013-07-23 | Wyeth Llc | Stability in vitamin and mineral supplements |
WO2020182831A1 (en) * | 2019-03-11 | 2020-09-17 | Pignitter Marc | Food supplement |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2038157A (en) * | 1978-12-29 | 1980-07-23 | Saiki Y | Complete diet foods |
US4298601A (en) * | 1972-03-06 | 1981-11-03 | Technutra, S.A. | Method and formulations for the treatment of obesity |
JPH08259461A (en) * | 1995-03-24 | 1996-10-08 | Snow Brand Milk Prod Co Ltd | Lipometabolism improver |
EP0739629A1 (en) * | 1995-04-28 | 1996-10-30 | Ravi Shrivastava | Associations comprising (-)hydroxycitrate and having new therapeutical activities |
FR2747308A1 (en) * | 1996-04-11 | 1997-10-17 | Shrivastava Ravi | Use of azadirachta indica, hydroxycitrate, ceramides and optionally vitamins or caffeine |
FR2747307A1 (en) * | 1996-04-11 | 1997-10-17 | Ravi Shrivastava | Use of ceramide(s), preferably with added magnesium and vitamin E |
WO1998017671A1 (en) * | 1996-10-22 | 1998-04-30 | Ravi Shrivastava | Magnesium (-)hydroxycitrate, method of preparation, applications, and compositions in particular pharmaceutical containing same |
FR2801214A1 (en) * | 1999-11-24 | 2001-05-25 | Ravishekhaz Shrivastava | Rapid reduction of stomach diameter, comprises a synergistic combination of an oral preparation containing plant extracts and clay and a local preparation containing essential oils and gel |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1356370A (en) * | 1972-03-06 | 1974-06-12 | Howard A N | Methods and formulations for the treatment of obesity |
US5340315A (en) * | 1991-06-27 | 1994-08-23 | Abbott Laboratories | Method of treating obesity |
AU2002221934A1 (en) * | 2000-12-16 | 2002-06-24 | Aventis Pharma Deutschland Gmbh | Health promoting compositions |
-
2002
- 2002-04-19 FR FR0204905A patent/FR2838645B1/en not_active Expired - Fee Related
-
2003
- 2003-10-17 AU AU2003254759A patent/AU2003254759B2/en not_active Ceased
- 2003-10-22 CA CA2446254A patent/CA2446254C/en not_active Expired - Fee Related
- 2003-10-24 JP JP2003364492A patent/JP2005126379A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4298601A (en) * | 1972-03-06 | 1981-11-03 | Technutra, S.A. | Method and formulations for the treatment of obesity |
GB2038157A (en) * | 1978-12-29 | 1980-07-23 | Saiki Y | Complete diet foods |
JPH08259461A (en) * | 1995-03-24 | 1996-10-08 | Snow Brand Milk Prod Co Ltd | Lipometabolism improver |
EP0739629A1 (en) * | 1995-04-28 | 1996-10-30 | Ravi Shrivastava | Associations comprising (-)hydroxycitrate and having new therapeutical activities |
FR2747308A1 (en) * | 1996-04-11 | 1997-10-17 | Shrivastava Ravi | Use of azadirachta indica, hydroxycitrate, ceramides and optionally vitamins or caffeine |
FR2747307A1 (en) * | 1996-04-11 | 1997-10-17 | Ravi Shrivastava | Use of ceramide(s), preferably with added magnesium and vitamin E |
WO1998017671A1 (en) * | 1996-10-22 | 1998-04-30 | Ravi Shrivastava | Magnesium (-)hydroxycitrate, method of preparation, applications, and compositions in particular pharmaceutical containing same |
FR2801214A1 (en) * | 1999-11-24 | 2001-05-25 | Ravishekhaz Shrivastava | Rapid reduction of stomach diameter, comprises a synergistic combination of an oral preparation containing plant extracts and clay and a local preparation containing essential oils and gel |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Section Ch Week 199650, Derwent World Patents Index; Class B04, AN 1996-502640, XP002229490 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1598063A1 (en) * | 2003-10-22 | 2005-11-23 | Ravi Shrivastava | Synergic compositions comprising vitamins, minerals and trace elements to stimulate removal of intracellular lipids |
FR2883472A1 (en) * | 2005-03-23 | 2006-09-29 | Biolog Vegetale Yves Rocher Sa | Use of a chlorogenic acid in active agents for slimming in cosmetics |
Also Published As
Publication number | Publication date |
---|---|
CA2446254C (en) | 2012-01-03 |
AU2003254759A1 (en) | 2005-05-05 |
CA2446254A1 (en) | 2005-04-22 |
AU2003254759B2 (en) | 2009-09-03 |
JP2005126379A (en) | 2005-05-19 |
FR2838645B1 (en) | 2004-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090110674A1 (en) | Health supplement | |
ES2254721T3 (en) | COMPOSITION TO REDUCE THE APPETITE IN MAMMALS UNDERSTANDING PROCIANIDINE | |
KR101320374B1 (en) | Health Supplement Food, Feed, and Pharmaceutical Composition Comprising Chia Seed and Maca, and Manufacturing Method thereof | |
Navarra | The encyclopedia of vitamins, minerals, and supplements | |
CN104902912A (en) | Synergistic dietary supplement compositions for enhancing physical performance and energy levels | |
KR101687982B1 (en) | Composition for improving sexual functionality having effects of increasing of the number of sperm and protection of environmental hormone and manufacturing method thereof | |
CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
CN108618126A (en) | A kind of Chinese medicine compound prescription weight-reducing special diet food and preparation method thereof | |
TW200838496A (en) | Agent for alleviating or preventing stress symptoms and agent for improving mental conditions | |
WO2006021930A2 (en) | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp | |
CN100579545C (en) | Health-care wine with sleeping improving and beauty functions and its preparing process | |
FR3095761A1 (en) | Nutraceutical composition to induce weight loss and reduce abdominal fat | |
FR2838645A1 (en) | Reducing intracellular accumulation of lipids and treating obesity, by oral or local administration of synergistic combination of at least two vitamins and at least two minerals or trace elements | |
FR2861594A1 (en) | COMPOSITION CONTAINING EXTRACT OF GREEN AND VITAMIN C | |
CN105101817B (en) | Edible composition and preparation method thereof and the food comprising said composition | |
US20180169071A1 (en) | Nutritional supplement composition | |
US20050266096A1 (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits | |
EP1598063A1 (en) | Synergic compositions comprising vitamins, minerals and trace elements to stimulate removal of intracellular lipids | |
JP2000316528A (en) | Nutrition supplementing food for enhancing reproductive function | |
FR2849601A1 (en) | Synergistic, plant extract-based, non-solid oral composition, useful e.g. for reducing weight or stress, contains vitamins and minerals or trace elements to improve bioavailability and efficacy | |
JP2001321126A (en) | Food composition | |
RU2489039C2 (en) | Biologically active food supplement with tonic and adaptogenic effect | |
FR2801214A1 (en) | Rapid reduction of stomach diameter, comprises a synergistic combination of an oral preparation containing plant extracts and clay and a local preparation containing essential oils and gel | |
BATUBARA et al. | Evolving potential functional foods to meet modern needs in commercial product | |
KR101100904B1 (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ST | Notification of lapse |
Effective date: 20081231 |
|
RN | Application for restoration | ||
FC | Decision of inpi director general to approve request for restoration | ||
ST | Notification of lapse |
Effective date: 20100630 |
|
RN | Application for restoration | ||
FC | Decision of inpi director general to approve request for restoration | ||
PLFP | Fee payment |
Year of fee payment: 15 |
|
ST | Notification of lapse |
Effective date: 20171229 |